Clinical trials: Peritoneal Mesothelioma
- Condition Peritoneal Mesothelioma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
- Trial name
- Tremelimumab (NCT01843374)
- Testing
- Tremelimumab
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 571 people
- Sponsor
- MedImmune LLC